This notice in TED website: https://ted.europa.eu/udl?uri=TED:NOTICE:112326-2019:TEXT:EN:HTML

United Kingdom-Runcorn: Blood coagulants 2019/S 049-112326

Contract award notice

Results of the procurement procedure

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

The NHS Commissioning Board (Operating under the name of NHS England)

2nd Floor, Rutland House

Runcorn

WA7 2ES

United Kingdom

E-mail: philip.grieve@nhs.net

NUTS code: UK Internet address(es):

Main address: https://nhsengland.bravosolution.co.uk

1.2) Information about joint procurement

The contract is awarded by a central purchasing body

1.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

1.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

NHS Framework Agreement for the Supply of Recombinant Factor IX Products for the Treatment of Haemophilia B

Reference number: CM/PHS/17/5534

II.1.2) Main CPV code

33141530

II.1.3) Type of contract

Supplies

II.1.4) Short description:

NHS National Framework Agreement for the supply of Recombinant Factor IX products for the treatment of Haemophilia B. The framework is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland. The framework may also be used

1/6

by private sector contractors and agents working on behalf of the above. The framework will commence on 1.3.2019 for a period of 24 months until 28.2.2021, with options to extend for a further 24 months. Please refer to the Invitation to Offer documents for the list of purchasing points.

II.1.6) Information about lots

This contract is divided into lots: no

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: 192 000 000.00 GBP

II.2) Description

- II.2.1) **Title:**
- II.2.2) Additional CPV code(s)

II.2.3) Place of performance

NUTS code: UK

Main site or place of performance:

Please refer to Document No.04d in the ITO for the list of purchasing points.

II.2.4) **Description of the procurement:**

NHS National Framework Agreement for the supply of Recombinant Factor IX products for the treatment of Haemophilia B. The framework is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland. The framework may also be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.3.2019 for a period of 24 months until 28.2.2021, with options to extend for a further 24 months. Please refer to the Invitation to Offer documents for the list of purchasing points.

II.2.5) Award criteria

Quality criterion - Name: Price / Weighting: 80 %

Quality criterion - Name: Security of Supply / Weighting: 5 % Quality criterion - Name: Ease of Use / Weighting: 15 %

Cost criterion - Name: Price / Weighting: 80 %

Cost criterion - Name: Security of Supply / Weighting: 5% Cost criterion - Name: Ease of Use / Weighting: 15%

II.2.11) Information about options

Options: no

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) Additional information

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

IV.1.6) Information about electronic auction

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S: 2018/S 214-489924

IV.2.8) Information about termination of dynamic purchasing system

IV.2.9) Information about termination of call for competition in the form of a prior information notice

Section V: Award of contract

Contract No: CM/PHS/17/5534

Title:

NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of Haemophilia B

A contract/lot is awarded: yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract:

15/02/2019

V.2.2) Information about tenders

Number of tenders received: 5

Number of tenders received from SMEs: 1

The contract has been awarded to a group of economic operators: no

V.2.3) Name and address of the contractor

CSL Behring (UK) Ltd

Haywards Heath

United Kingdom

NUTS code: UK

The contractor is an SME: no

V.2.4) Information on value of the contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: 1.00 GBP

Total value of the contract/lot: 1.00 GBP

V.2.5) Information about subcontracting

Section V: Award of contract

Contract No: CM/PHS/17/5534

Title:

NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of Haemophilia B

A contract/lot is awarded: yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract:

15/02/2019

V.2.2) Information about tenders

Number of tenders received: 5

Number of tenders received from SMEs: 1

The contract has been awarded to a group of economic operators: no

V.2.3) Name and address of the contractor

Novo Nordisk Ltd

Gatwick

United Kingdom NUTS code: UK

The contractor is an SME: no

V.2.4) Information on value of the contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: 1.00 GBP

Total value of the contract/lot: 1.00 GBP

V.2.5) Information about subcontracting

Section V: Award of contract

Contract No: CM/PHS/17/5534

Title:

NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of Haemophilia B

A contract/lot is awarded: yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract:

15/02/2019

V.2.2) Information about tenders

Number of tenders received: 5

Number of tenders received from SMEs: 1

The contract has been awarded to a group of economic operators: no

V.2.3) Name and address of the contractor

Pfizer Ltd

Tadworth

United Kingdom NUTS code: UK

The contractor is an SME: no

V.2.4) Information on value of the contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: 1.00 GBP

Total value of the contract/lot: 1.00 GBP

V.2.5) Information about subcontracting

Section V: Award of contract

Contract No: CM/PHS/17/5534

Title:

NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of Haemophilia B

A contract/lot is awarded: yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract:

15/02/2019

V.2.2) Information about tenders

Number of tenders received: 5

Number of tenders received from SMEs: 1

The contract has been awarded to a group of economic operators: no

V.2.3) Name and address of the contractor

Shire Pharmaceuticals Ltd

London

United Kingdom NUTS code: UK

The contractor is an SME: no

V.2.4) Information on value of the contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: 1.00 GBP

Total value of the contract/lot: 1.00 GBP

V.2.5) Information about subcontracting

Section V: Award of contract

Contract No: CM/PHS/17/5534

Title

NHS Framework Agreement for the Supply of Recombinant Factor 1X Products for the Treatment of

Haemophilia B

A contract/lot is awarded: yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract:

15/02/2019

V.2.2) Information about tenders

Number of tenders received: 5

Number of tenders received from SMEs: 1

The contract has been awarded to a group of economic operators: no

V.2.3) Name and address of the contractor

Swedish Orphan Biovitrum Ltd

Great Abington

United Kingdom

NUTS code: UK

The contractor is an SME: yes

V.2.4) Information on value of the contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: 1.00 GBP

Total value of the contract/lot: 1.00 GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information:

Commercial Medicines Unit Employee.

VI.4) Procedures for review

VI.4.1) Review body

The NHS Commissioning Board (operating under the name of NHS England)

Runcorn

United Kingdom

- VI.4.2) Body responsible for mediation procedures
- VI.4.3) Review procedure
- VI.4.4) Service from which information about the review procedure may be obtained
- VI.5) Date of dispatch of this notice:

06/03/2019